Sahhamed

Decentralized clinical-study teams can want sleep and activity signals without building every mobile and data-control component. The supplied research confirms a live passive-biomarker provider with mobile integrations, endpoints and webhooks, while enterprise decentralized-study platforms remain close alternatives. It reports no reviewed sub-enterprise integration kit combining that provider with an audit envelope and sponsor workflow. Two of four referenced interface capabilities remain unverified.

Sahhamed would preserve sponsor, study, protocol, site, participant token, consent version, consent status, device, operating-system version, provider, provider SDK version, provider account, data permission, collection window, raw event reference, source timestamp, receipt timestamp, missing interval, sensor quality assertion, derived biomarker, algorithm version, unit, baseline period, anomaly candidate, protocol endpoint mapping, intended use, validation requirement, validation plan, test case, test result, deviation, electronic record, signer assertion, signature meaning, audit event, correction, data query, investigator review, sponsor approval, export version, retention and deletion as distinct records.

Consumer or wellness-derived biomarkers are not validated clinical endpoints merely because an interface exposes them. Missing wear time, device changes, algorithm updates and participant behavior can alter signals. Append-only storage supports integrity but does not establish accuracy, attributable authorship or regulatory compliance. Sahhamed must not diagnose, monitor participant safety autonomously, replace investigator judgment, claim conformity with electronic-record or decentralized-trial requirements, infer consent, change endpoints or submit regulatory materials without sponsor and qualified validation approval.

The pilot should use synthetic participants, sandbox provider accounts and a non-interventional protocol simulation. The likely buyer is a digital-clinical, data-management, clinical-operations or quality leader at a smaller sponsor or study-services organization. Intended use, endpoint acceptance, current regulatory guidance, provider licensing, consent design, device support, validation ownership, safety monitoring, study scale, budget and differentiation from enterprise platforms remain unverified.

A digital-clinical, data-management, clinical-operations or quality leader at a smaller study sponsor or services organization.